Dantrium IV - Malignant Hyperthermia

United States

P&G Network Search

Pharmaceuticals:
US Products

Consumers:

Health Care Professionals:

FDA APPROVES NEW ONCE-A-MONTH DOSE OF ACTONEL FOR POSTMENOPAUSAL OSTEOPOROSIS

CINCINNATI, Bridgewater, NJ, April 24, 2008 — The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel� (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
More:

Dantrium® Intravenous (dantrolene sodium for injection)

Dantrium^® Intravenous (dantrolene sodium for injection)

Effective August 19, 2008, JHP Pharmaceuticals, LLC (JHP) acquired the marketing and distribution rights from Procter & Gamble Pharmaceuticals, Inc. (P&GP) for Dantrium� (dantrolene sodium) capsules and Dantrium� Intravenous (dantrolene sodium for injection).

For information on Dantrium products in the US, please contact JHP at www.jhppharma.com or call customer service at 1.877.547.4547.

For information Dantrium products in Canada, please call 1.800.265.8676

To find out more about Dantrium I.V., click here:
Dantrium IV Product Information (PDF Format)

Can't view the PDF?
Click here to download Adobe Acrobat.

Explore P&GP Products: Actonel ® Asacol ® Dantrium ® Dantrium ® IV Didronel ® Enablex ® Macrobid ® Macrodantin ®




	©2008 Procter & Gamble. All claims valid only in the U.S. Legal Information Privacy Statement P&G Links